This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Antenatal corticosteroid therapy for fetal pulmonary maturation and the prevention of intraventricular hemorrhage is indicated for women who are at risk for premature delivery and results in a substantial decrease in neonatal morbidity and mortality.¹ Currently, women with maternal diabetes are at increased risk for neonatal morbidity and mortality, and it predisposes the preterm infant to respiratory distress syndrome (RDS), especially when poorly controlled diabetes gives rise to fetal hyperinsulinism that blocks surfactant production by pulmonary cells, and the use of antenatal steroids can be justified.¹

Continuous subcutaneous insulin infusion (CSII) is sometimes indicated to improve metabolic control during pregnancy.² One potential complication that is peculiar to CSII is ketoacidosis; it is observed at rate of 0.15 to 0.4 episodes per patient per year.³ There is also the increased risk of gestational diabetes with corticosteroid therapy,⁴ but the influence on glycemic control in pregnant women with type 1 diabetes who . . . [Full Text of this Article]

Report of Cases

Case 1

Case 2

Comment

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Management of Diabetes and Hyperglycemia in Hospitals
Clement et al.
Diabetes Care 2004;27:553-591.
FULL TEXT